Dominari Holdings Inc. (DOMH) AI Stock Analysis
DOMH AI stock analysis summary
AI ResearchDominari Holdings Inc. (DOMH) is a biotechnology firm advancing small-molecule anti-cancer therapies and antiviral platforms. In FY2025, revenue expanded to $123.1M while generating $22.7M in operating cash flow, but net income remained negative at -$22.4M. Over the past year, the stock fell 59.4% to $1.96, leaving its market capitalization at $47.5M.
- Market cap
- $47.5M
- Revenue (TTM)
- $129.4M
- P/E
- —
- 1Y return
- -59.4% S&P 500 16.8%
- Avg. target
- $16.00 716.3% vs last close
Bull case
- Dominari delivered $22.7M in operating cash flow and free cash flow in FY2025.
- The company maintains a solid balance sheet with $29.3M in net cash and a current ratio of 1.80 as of June 30, 2026.
- Analysts maintain a mean price target of $16.00, representing 716.3% upside from the last closing price of $1.96.
Bear case
- The company remains unprofitable, reporting a trailing twelve month net profit margin of -53.2% and EPS of -$5.23.
- In the latest quarter ended June 30, 2026, quarterly revenue fell 56.9% year-over-year.
- Shareholders experienced substantial dilution, with the share count increasing by 333.2% over 5 years.
What Dominari does
Based in New York, Dominari Holdings Inc., formerly known as AIkido Pharma Inc., is a biotechnology company focused on developing small-molecule anti-cancer therapies and an antiviral platform. Its oncology pipeline targets challenging cancers including prostate cancer, pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia, with key drug candidates DHA-dFdC and KPC34. The company's antiviral program aims to inhibit viruses such as influenza, Ebolavirus, Marburg virus, and coronaviruses including SARS-CoV-2. Dominari leverages licensing agreements with institutions such as the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Growth and profitability
Dominari saw rapid revenue expansion from $9,000 in FY2020 and $2.0M in FY2023 to $18.1M in FY2024 and $123.1M in FY2025, achieving a 5-year revenue CAGR of 571.7%. However, profitability has remained negative, recording a net income of -$14.7M in FY2024 and -$22.4M in FY2025 with an operating margin of -45.3%. For the trailing twelve months ended June 30, 2026, revenue stood at $129.4M with a profit margin of -53.2% and EPS of -$5.23. In the latest quarter, revenue declined 56.9% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Dominari held $31.9M in cash and short-term investments against $2.6M in total debt, yielding net cash of $29.3M. The company maintains a current ratio of 1.80, a debt-to-equity ratio of 0.12, and shareholders' equity of $21.8M against total assets of $57.4M. In FY2025, the business produced $22.7M in free cash flow and paid $11.9M in dividends, while its share count grew 333.2% over 5 years.
Valuation and performance
At a market cap of $47.5M and enterprise value of $28.0M, Dominari trades at an EV-to-revenue multiple of 0.2x and a price-to-sales multiple of 0.4x, well below the 3.2x median of its US-listed Financial Services peers. Its EV-to-EBITDA ratio stands at 1.7x compared to the peer median of 11.7x, while its price-to-book ratio is 2.4x. Over the past year, DOMH shares dropped 59.4%, underperforming the S&P 500 (SPY), which gained 16.8%.
What analysts expect
Wall Street analysts set a mean price target of $16.00 for Dominari Holdings, representing a 716.3% premium over its last close of $1.96 on October 16, 2026. Over the last four quarters, the company met or beat EPS expectations 2 times. The company's next earnings report is scheduled for November 9, 2026, as investors track its progress following a trailing twelve month EPS of -$5.23.
Key risks and what to watch
- DOMH shares have declined 59.4% over the past year and sit 32.4% below their 200-day average.
- Return on equity of -122.8% and return on assets of -81.4% highlight severe ongoing capital losses.
- The company faces revenue volatility, as quarterly revenue dropped 56.9% year-over-year in the quarter ended June 30, 2026.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this DOMH AI stock analysis
This page is an AI-written research summary of Dominari Holdings Inc. (DOMH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: DOMH income statement, DOMH balance sheet, DOMH key metrics, DOMH chart. See the DOMH stock overview for the latest quote and news.
DOMH AI stock analysis FAQ
What does Dominari Holdings Inc. do?
Dominari Holdings Inc. is a biotechnology company developing small-molecule anti-cancer therapies such as DHA-dFdC and KPC34, as well as an antiviral platform targeting multiple viruses.
When is Dominari Holdings' next earnings date?
The company's next earnings release is scheduled for November 9, 2026.
What is Dominari's cash and debt position?
As of June 30, 2026, Dominari held $31.9M in cash and short-term investments alongside $2.6M in total debt, resulting in net cash of $29.3M.
What is the analyst price target for DOMH?
Analysts have established a mean price target of $16.00, which sits 716.3% above the stock's closing price of $1.96 on October 16, 2026.